AstraZeneca PLC operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares AstraZeneca PLC with three other
pharmaceutical manufacturers in Europe:
Novo Nordisk As
of Denmark
(2017
sales of 111.70 billion Danish Kroner [US$18.55 billion]
of which 83%
was Diabetes Care),
Merck KGaA
of Germany
(15.33 billion Euro [US$18.97 billion]
of which 46%
was Healthcare), and
Shire PLC
(£11.64 billion [US$16.63 billion]
of which 100%
was Pharmaceuticals & Genetic Therapies).
Sales Analysis.
During the year ended December of 2017, sales at
AstraZeneca PLC were £17.25 billion (US$24.65 billion).
This
is
a very small
increase of 0.9%
versus 2016, when the company's sales were £17.11 billion.
This was the third consecutive year of growth at AstraZeneca PLC.
The sales level in 2017 was fairly close to the level five years ago: in 2012, AstraZeneca PLC had sales
of £17.56 billion.